

23th Annual

# Market Access

Summit



**October 29 & 30, 2024**

Hyatt Regency Toronto  
Toronto, ON

**The largest and  
longest-running market access**

**conference in Canada**

---

Driving Customer Growth Through Impactful Digital Marketing & Experience Strategies

# **International collaboration in HTA**

**Dr Kendall Jamieson Gilmore**  
**Associate Director of Strategy**  
**NICE**

# International collaboration in HTA

1. Introduction to NICE and our priorities
2. International collaboration in HTA

# Introduction to NICE and our priorities

# The health and care system is changing




We're seeing:

- health service pressures
- shared decision making
- growth in innovation
- vast amounts of data.

**NICE**

## NICE is transforming too

NICE's core purpose remains the same: to help practitioners and commissioners get the best care to people fast, while ensuring value for the taxpayer.




But as the NHS transforms to meet future challenges, we need to play our part too.

# How we're transforming...

While preserving our core principles of transparency, rigour and independence, we're focussed on developing guidance that is...

**More timely and  
easy to use**




...by providing timely and useable advice.

**More relevant**



...by focusing on what matters most.

**Greater demonstrable  
impact**



...by learning from data and implementation.

# The progress we've made

In 2023/24, we delivered significant improvements and invested in foundational programmes of work that we'll develop further over the next few years.

## More timely and easier to use

Streamlined technology appraisals are now up to

**45% faster**

than our standard approach, following methods and process updates.



We published guidance on 2 medicines within

**24 hours**

of marketing authorisation, for the first time ever.



## More relevant

We're ensuring our guidance focuses on **what matters most to health and care** through a new integrated approach to topic selection and prioritisation.



We grew **enquiries to NICE Advice** **by 82%**

following its relaunch as a more flexible and accessible support service for industry.



## Greater demonstrable impact

We've measured uptake of **NICE recommendations** in

**19 priority topics**

to help focus our implementation support and increase the impact of our advice.



# Key achievements

Throughout 2023/24, we responded to health system needs by delivering a range of high-quality outputs and improving our ways of working.

## More timely and easier to use

**36 days:**

average time to medicines access following regulatory approval in optimal\* appraisals.



Our **NICE Advice service** is now much easier for healthtech developers to access and use following the launch of 1-hour surgery meetings.



## More relevant


Around  
**150,000**

adults and children with type 1 diabetes stand to benefit from a life-changing hybrid closed loop technology we recommended.



Our **digital health programme** is now

**>30 times bigger** than it was in 2021/22, assessing 105 technologies in 2023/24.



## Greater demonstrable impact

We measured national uptake of **147 quality standard statements** and **32 NICE-recommended medicines** when identifying areas for implementation support.



Increased use of **real-world evidence** in guideline development.

It featured in

**> 95%**

of guideline cost-effectiveness models.



\* Medicines satisfying criteria allowing NICE to publish final guidance within 90 days of marketing authorisation.



# What's next for 2024/25?

Building on last year's success we'll continue to focus on providing high quality, timely guidance that is easy to use, relevant and impactful.



## High quality, more timely and easier to use

- Speeding up NICE decisions on medicines and healthtech evaluations.
- Improving our assessment of value by expanding the HTA Lab and reviewing our approach to severity and health inequalities.
- Making our guidance even easier to access and use.



## More relevant

Ensuring our guidance focuses on what matters most through integrated horizon scanning, topic selection and prioritisation.



## More impactful

Increasing uptake of NICE guidance by:

- Expanding our use of insight to inform the focus of our implementation support.
- Providing more ways for people and communities to contribute to guidance development.

Improving user experience and impact by including medicine and healthtech recommendations in guidelines.

# International collaboration in HTA

# Why collaborate internationally as an HTA agency?

HTA paradigms  
challenged by  
developments in  
healthcare

Common challenges to  
HTA organisations  
internationally

HTA agency resource  
constraints

Agency specific  
expertise

Opportunity to support  
patient access to new  
treatments

Opportunity to support  
industry

# National features inform what works in international HTA collaboration

Local health system  
differences

HTA role and  
approach

National priorities and  
values

- Jurisdiction specific nature of HTA means the appraisal and decision is less transferable than decisions across regulators.
- For this reason, multi-national HTA initiatives do not go as far as regulatory initiatives.

# HTA collaborations vary widely in how far they work together

**AUS CAN NZ UK**

- Loose collaboration to identify and characterise issues of common interest, share and develop solutions.
- We have explored: work sharing, operational lessons, science and methods development.

**EU HTA**

- The EU HTA regulation is the largest international HTA initiative.
- From 2025 the regulation will support a joint clinical assessment for use in HTA processes in all EU countries.

**BENELUXA**

- Can share economics as well as clinical assessment.

**NICE**

# NICE collaborates internationally at multiple levels

Bilateral	Canada, USA, many European countries
Multilateral	AUS CAN NZ UK Collaborative
Networks	International Network of Agencies for Health Technology Assessment (INAHTA), Health Technology Assessment international (HTAi)
Grant funded research	International grant funded research projects e.g. Support the Utilisation of Sustainable and Tailored Innovative methods for HTA (SUSTAIN-HTA)

# NICE's multi-agency collaboration is focussed on pre-evaluation activities

1

Horizon scanning

2

Aligning methods and positions

3

Supporting industry directly on evidence generation plans

# 1 International collaboration on horizon scanning

## Why?

- Shared understanding of pipeline and appraisals which may require heightened focus
  - Enables early development of methods as needed, commissioning evidence, preparing system for delivery
- 

## How?

- Information sharing to identify potentially significant appraisals
  - Exchange work programmes and topics under consideration for assessment
- 

## Actions taken

- Preparatory work for innovative medicines e.g. first histology independent cancer drugs, supporting health system preparedness for new medicines
- Establishing longer term horizon scanning view to inform preparedness



## 2 International alignment of methods and positions

### Why?

- Provide global consistency and clear expectations of industry on internationally relevant issues
  - Minimise burden of HTA for global launches where possible
- 

### How?

- Time limited collaborative initiatives that support alignment of methods.
  - Agencies involved vary depending on the issues in question.
- 

### Actions taken

- Academic in confidence position statement
- Multi-agency consensus recommendations on use of surrogates.

**NICE**

# 3 Parallel scientific advice

## Why?

- Consistent voice from HTA agencies can support evidence generation and application of the methodology in company clinical development plans and global value dossiers

## How?

- Parallel NICE and CDA scientific advice, launched in 2019
- Companies receive joint summary that highlights areas of alignment as well as separate detailed reports from each agency

## Actions taken

- Parallel advice engagements continue
- Engagements have helped companies set up trials to enable access in both UK and Canada.

**NICE**

# Summary and key messages

- 1 HTA has many jurisdiction specific factors
- 2 Fruitful collaboration is possible; there is no single model
- 3 Horizon scanning, methods and positions, and joint scientific advice are key areas for NICE
- 4 Collaboration can benefit HTA agencies, industry and patients
- 5 Benefits include HTA and system readiness, greater clarity and simplicity for industry, aligned global HTA processes
- 6 Developers can seek joint scientific advice, notify new products, take note of shared positions

# Thank you